C-J0SDlipofuscin removal, retinal pigment epithelium, ophthalmology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Treat dry age-related macular degeneration by removing lipofuscin from living retinal pigment epithelium cells.
Remofuscin drug program targeting lipofuscin removal in retinal pigment epithelium cells for dry age-related macular degeneration.
Company site analysis states the dry age-related macular degeneration indication is entering Phase 2.
Treat Stargardt disease by removing or reducing lipofuscin from living retinal pigment epithelium cells, with clinical evaluation of safety and efficacy in genetically confirmed STGD1 patients.
Oral Remofuscin 20 mg in the double-masked, placebo-controlled STArgardt Remofuscin Treatment Trial, using qAF8 as the primary outcome and BCVA, LLVA, microperimetry, SD-OCT, reading speed, NEI VFQ-25, and FRI Index as secondary measures.
STARTT enrolled 87 randomized Stargardt disease patients; public materials state the Stargardt indication was entering Phase 2, and BioRegio STERN reported enrolment completion.
Published baseline data characterized the enrolled STGD1 cohort and qAF imaging; a later multicenter analysis found qAF repeatability was variable but usable as a clinical trial endpoint with improved operator training and selection of better recordings. No efficacy result is supplied.